- Chemical carcinogenesis and radiation carcinogenesis
- Experimental animal models and genetically-engineered animals
- Virus, infection, inflammation and cancer
- Oncogenes and tumor-suppressor genes
- Signal transduction and gene expression
- DNA replication/cell cycle/genomic instability
- Cancer genome/genetics
- Cell death/immortalization
- Epigenetics
- Invasion and metastasis
- Characteristics of cancer cells
- Cancer immunity
- Growth factors/cytokines/hormones
- Cancer basic, diagnosis and treatment
- Diagnosis
- Molecular-targeting therapy
- Chemotherapy and endocrine therapy
- Evaluation and prediction of pharmacological effects
- Radiation therapy
- Cell therapy and regeneration medicine
- Gene therapy
- Medical care of progressive cancer
- Cancer prevention/chemoprevention
- Epidemiology
- Information/informatics
- Cancer and society
1. Chemical carcinogenesis and radiation carcinogenesis
1-1 | Activation and metabolism of carcinogens |
---|---|
1-2 | Detection and assessment of carcinogens |
1-3 | DNA damage |
1-4 | Process of carcinogenesis |
1-5 | Nitric oxide/reactive oxygen |
1-6 | Genotoxins and nongenotoxins |
1-7 | Experimental cell culture systems |
1-8 | Radiation and electromagnetic wave carcinogenesis |
1-9 | Others |
2. Experimental animal models and genetically-engineered animals
2-1 | Gene-manipulated animal models |
---|---|
2-2 | Animal model for carcinogenesis |
2-3 | Patient-derived experimental model |
2-4 | Others |
3. Virus, infection, inflammation and cancer
3-1 | EBV |
---|---|
3-2 | HPV |
3-3 | HBV |
3-4 | HCV |
3-5 | HTLV-1 |
3-6 | HHV-8 |
3-7 | H.pylori |
3-8 | Other viruses/bacteria |
3-9 | Intestinal bacteria/microbiome |
3-10 | Inflammation and cancer |
4. Oncogenes and tumor-suppressor genes
4-1 | ras family genes |
---|---|
4-2 | p53-related genes |
4-3 | Rb/p16-related genes |
4-4 | Wnt signaling-related genes |
4-5 | Chromosomal translocation-related genes |
4-6 | Other oncogenes/tumor-suppressor genes |
4-7 | Novel oncogenes/tumor-suppressor genes |
5. Signal transduction and gene expression
5-1 | Proliferation/differentiation |
---|---|
5-2 | Signal transduction |
5-3 | Transcriptional regulation |
5-4 | Translational regulation |
5-5 | RNA engineering |
5-6 | ncRNA・microRNA |
5-7 | Others |
6. DNA replication/cell cycle/genomic instability
6-1 | Cell cycle/checkpoint |
---|---|
6-2 | DNA replication |
6-3 | DNA repair |
6-4 | Genetic instability |
7. Cancer genome/genetics
7-1 | Genomic analysis |
---|---|
7-2 | Genomic medicine |
7-3 | NGS |
7-4 | Genome editing |
7-5 | Homozygous deletion/positional cloning |
7-6 | Chromosomal translocation/gene rearrangement |
7-7 | Gene amplification |
7-8 | Familial tumor and target genes |
7-9 | Carcinogenic sensitivity-related genes (SNPs) |
7-10 | Others |
8. Cell death/immortalization
8-1 | Cell death |
---|---|
8-2 | Telomere/senescence/immnortalization |
8-3 | Others |
9. Epigenetics
9-1 | DNA methylation |
---|---|
9-2 | Histone modification |
9-3 | Chromatin structure |
9-4 | Others |
10. Invasion and metastasis
10-1 | Cell adhesion/invasion |
---|---|
10-2 | Extracellular matrices and proteases |
10-3 | Metastasis-associated genes |
10-4 | Angiogenesis |
10-5 | Diagnosis of metastasis |
10-6 | Metastasis inhibition |
10-7 | Metastasis models |
10-8 | Others |
11. Characteristics of cancer cells
11-1 | Cancer stem cells |
---|---|
11-2 | Cell differentiation |
11-3 | Cell-to-cell interaction/adhesion molecules |
11-4 | Cell lines |
11-5 | Organoid |
11-6 | Carbohydrate chains and glycosyltransferases |
11-7 | Extracellular vesicles/Exosome |
11-8 | Metabolism / Metabolome |
11-9 | Others |
12. Cancer immunity
12-1 | Innate immunity |
---|---|
12-2 | Dendritic cells/antigen-presenting cells |
12-3 | Tumor antigens |
12-4 | Antitumor effector cells and their induction |
12-5 | Immune checkpoint inhibitors |
12-6 | Vaccination therapy |
12-7 | Antibody therapy |
12-8 | Other immunotherapies |
12-9 | Others |
13. Growth factors/cytokines/hormones
13-1 | Growth- and differentiation-regulating factors |
---|---|
13-2 | Growth factor receptors |
13-3 | Hormones |
13-4 | Cytokines |
13-5 | TGF-b/Smad |
14. Cancer basic, diagnosis and treatment
14-1 | Gastric cancer |
---|---|
14-2 | Esophageal cancer |
14-3 | Colorectal cancer |
14-4 | GIST |
14-5 | Hepatocellular cancer |
14-6 | Carcinoma of the biliary tract |
14-7 | Pancreatic cancer |
14-8 | Lung cancer |
14-9 | Breast cancer |
14-10 | Uterine cancer |
14-11 | Ovarian cancer |
14-12 | hematopoietic malignancy |
14-13 | Renal cell cancer |
14-14 | Bladder cancer |
14-15 | Prostatic cancer |
14-16 | Testicular cancer |
14-17 | Brain tumor |
14-18 | Primary bone tumor |
14-19 | Soft tissue sarcoma |
14-20 | Head and neck cancer |
14-21 | Endocrine cancer |
14-22 | Skin cancer |
14-23 | Childhood cancer/AYA |
14-24 | Other organs |
15. Diagnosis
15-1 | Pathological diagnosis |
---|---|
15-2 | Diagnostic imaging |
15-3 | Diagnosis by tumor markers and biomarkers |
15-4 | Genomic diagnostics |
15-5 | Diagnosis by expression analysis (mRNA, protein) |
15-6 | Novel diagnostic technology |
15-7 | Liquid biopsy |
15-8 | Artificial intelligence based diagnostics |
15-9 | Others |
16. Molecular-targeting therapy
16-1 | Signal transduction inhibitors/kinase inhibitors |
---|---|
16-2 | Angiogenesis inhibitors/antimetastatic drugs |
16-3 | Cell cycle inhibitors (CDK inhibitors etc.) |
16-4 | Transcription modulators (histone deacetylase inhibitors etc.) |
16-5 | Others |
17. Chemotherapy and endocrine therapy
17-1 | Natural anticancer compounds |
---|---|
17-2 | Synthetic anticancer compounds |
17-3 | DNA-damaging drug (Platinum compounds/Topoisomerase inhibitors etc.) |
17-4 | Antimetabolites |
17-5 | Antimicrotubular drugs (taxane/alkaloids etc.) |
17-6 | Anticancer drug resistance |
17-7 | Anticancer drug and cell death |
17-8 | Endocrine therapy |
17-9 | Differentiation-inducing therapy |
17-10 | Drug delivery system |
17-11 | Combinational therapy/adjuvant therapy |
17-12 | Others |
18. Evaluation and prediction of pharmacological effects
18-1 | Drug sensitivity/drug resistance-relating factors/gene expression analysis |
---|---|
18-2 | Pharmacokinetics/pharmacodynamics (PK/PD) |
18-3 | Pharmacogenomics/toxicogenomics (SNPs, transcriptome, proteome) |
18-4 | Sensitivity test |
18-5 | Clinical trial |
18-6 | Biobank |
19. Radiation therapy
19-1 | Radiation and particle ray therapy |
---|---|
19-2 | Radiation hazard/protection |
19-3 | Radiosensitivity |
19-4 | Efficacy enhancement |
19-5 | Hyperthermia |
19-6 | Others |
20. Cell therapy and regeneration medicine
20-1 | Stem cells |
---|---|
20-2 | Regenerative medicine |
20-3 | Cell therapy of allograft |
20-4 | Others |
21. Gene therapy
21-1 | Generation and modification of vectors |
---|---|
21-2 | Immunogenetic therapy |
21-3 | Oncogene/tumor-suppressor gene therapy |
21-4 | Suicide gene therapy |
21-5 | Nucleic acid therapeutics (including DDS) |
21-6 | Others |
22. Medical care of progressive cancer
22-1 | Psychooncology |
---|---|
22-2 | Palliative treatment and care |
22-3 | Others |
23. Cancer prevention/chemoprevention
23-1 | Mechanism of cacinogenesis inhibition |
---|---|
23-2 | Synthetic compounds |
23-3 | Natural products |
23-4 | Dietary/alimentary factors |
23-5 | Others |
24. Epidemiology
24-1 | Environmental factors (life habits etc.)/infectious exposure |
---|---|
24-2 | Cancer prone syndromes/molecular epidemiology |
24-3 | Cohort study |
24-4 | Descriptive epidemiology/cancer registration |
24-5 | Cancer screening |
24-6 | Others |
25. Information/informatics
25-1 | Bioinfomatics |
---|---|
25-2 | Management and analysis of cancer patients' data |
25-3 | Others |
26. Cancer and society
26-1 | Informed consent |
---|---|
26-2 | Bioethics |
26-3 | Social movement against cancer |
26-4 | Smoking and drinking alcohol |
26-5 | Others |